WebView the latest Dyne Therapeutics Inc. (DYN) stock price, news, historical charts, analyst ratings and financial information from WSJ. WebApr 11, 2024 · Dyne Therapeutics Stock Performance. NASDAQ DYN opened at $8.82 on Tuesday. The stock has a market cap of $496.90 million, a price-to-earnings ratio of -2.72 and a beta of 0.24.
Dyne Therapeutics Inc (DYN) Stock Price & News - Google Finance
WebNov 3, 2024 · WALTHAM, Mass., Nov. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2024 and business … WebGet the latest Dyne Therapeutics, Inc. (DYN) stock news and headlines to help you in your trading and investing decisions. some eukaryotic organelles such as
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric ...
WebApr 13, 2024 · Dyne Therapeutics Inc (DYN) stock is trading at $8.97 as of 3:43 PM on Thursday, Apr 13, a gain of $0.44, or 5.19% from the previous closing price of $8.53. The stock has traded between $8.49 and $9.15 so far today. Volume today is 467,568 compared to average volume of 400,449. WebOct 31, 2024 · WALTHAM, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for ... WebMar 23, 2024 · Dyne Therapeutics, Inc. announced that DYNE-251, an investigational therapeutic for Duchenne muscular dystrophy mutations amenable to exon 51 skipping, was granted FDA orphan drug and rare pediatric disease designations.DYNE-251 is being evaluated in the Phase 1/2 DELIVER clinical trial. Under the FDA's rare pediatric disease … some evil beast hath devoured